USFDA adds Eli Lilly diabetes drug Mounjaro to list of drugs facing shortages Ruchika Sharma18 Dec 2022 2:00 PM ISTThe company is expanding its manufacturing capacity for the two drugs through its facility in North Carolina, and doubling it by the end of 2023.
Eli Lilly, EVA Pharma collaborate to provide affordable insulin to diabetic patients in Africa Ruchika Sharma15 Dec 2022 11:00 AM ISTIndianapolis: Eli Lilly and Company and EVA Pharma have announced a collaboration to deliver a sustainable supply of high-quality,...
Eli Lilly hopes to launch as many as 5 new treatments next year Ruchika Sharma14 Dec 2022 3:15 PM ISTIndianapolis: Eli Lilly and Co said on Tuesday it hopes to launch as many as five new treatments next year that could drive growth through the decade...
Eli Lilly concludes acquisition of Akouos Ruchika Sharma5 Dec 2022 11:30 AM ISTIndianapolis: Eli Lilly and Company has recently announced the successful completion of its acquisition of Akouos, Inc. "The acquisition...
COVID-19 Treatment : Eli Lilly's Bebtelovimab no longer authorized by USFDA Ruchika Sharma1 Dec 2022 3:30 PM ISTEli Lilly and its authorized distributors have paused the commercial distribution of the monoclonal antibody until further notice from the agency.
Eli Lilly unveils DCGI approved Ramiven in India for early stage breast cancer Ruchika Sharma24 Nov 2022 4:00 PM ISTRamiven (abemaciclib) is a targeted treatment known as a CDK4/6 inhibitor.
Eli Lilly ordered to pay Rs 1444 crore to Teva Pharma in US migraine drug patent trial Ruchika Sharma10 Nov 2022 2:00 PM ISTThe jury also found that Lilly infringed the patents willfully and rejected its argument that the patents were invalid.
Eli Lilly growth tied to nascent diabetes drug sales Ruchika Sharma1 Nov 2022 10:15 AM ISTUS: Wall Street analysts will be focusing on sales of Eli Lilly and Co's newly approved diabetes drug Mounjaro when the company reports results on...
Lilly to acquire Akouos for Hearing Loss treatments Ruchika Sharma19 Oct 2022 3:30 PM ISTUnder the terms of the transaction, Lilly will acquire all of the outstanding shares of Akouos for $12.50 per share in cash, plus one contingent value...
Eli Lilly gets USFDA Fast Track designation for Tirzepatide to treat adults with obesity Ruchika Sharma7 Oct 2022 12:15 PM ISTTirzepatide is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist.
USFDA nod to Eli Lilly RET Inhibitor Retevmo for adults with advanced or metastatic solid tumors with a RET Gene Fusion, regardless of type Ruchika Sharma23 Sept 2022 4:20 PM ISTIn addition to the tumor-agnostic approval, the USFDA has granted traditional approval for Retevmo in adult patients with locally advanced or...
FIRST: Eli Lilly gets USFDA nod for alopecia areata pill Olumiant Ruchika Sharma14 Jun 2022 1:00 PM ISTOLUMIANT is a once-daily, oral JAK inhibitor discovered by Incyte and licensed to Lilly and is available through specialty pharmacies nationwide.
